Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 2Phase 1 1

Status

Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Urothelial Cancer 1Prostatic Neoplasms 1Liposarcoma 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Midazolam × Clear all
NCT02365597 2026-05-08

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡